First-In-Class Drugs Are True Barometer Of Industry Innovation, FDA Says
Executive Summary
The agency suggests that categorizing approved drugs by level of novelty and tracking approvals by category is a better metric than NME count and should be the basis for assessment of the programs created by FDASIA to speed development of innovative products.